TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04110340
Drug: Streptomycin
Normalized name: Streptomycin
DrugBank: Streptomycin (DB01082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician.
Study: NCT04110340
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days.
Study: NCT03777657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
Study: NCT03777657
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
Study: NCT04428281
Drug: RO7248824
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Study: NCT01817192
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
Study: NCT00259441
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00688818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
Study: NCT00726726
Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
Study: NCT03494387
Drug: Antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants versus placebo
Study: NCT01261338
Drug: olestra
Normalized name: Beta Sitosterol/Campesterol/Stigmasterol 100 MG-50 MG-40 MG Oral Tablet [CHOLESTRATIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-absorbable dietary fat
Study: NCT04162873
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or via feeding tube
Study: NCT00566449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose daily for 4 weeks
Study: NCT04768101
Drug: [11C]-PIB
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]-PIB is a PET radiotracer used to evaluate levels of Αβ burden.
Study: NCT03490513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
Study: NCT02666898
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine
Study: NCT03894215
Drug: AGEN1884
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTLA-4 antibody
Study: NCT00980460
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00980460
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03579446
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT03579446
Drug: Oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT02673476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets
Study: NCT02549352
Drug: LEO43204 gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02549352
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337985
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02337985
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00719888
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04088227
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive platelet rich plasma injection two times prior to surgery.
Study: NCT02789605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
Study: NCT03858322
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
Study: NCT00646022
Drug: [18F]-DOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DOPA PET/CT Scan.
Study: NCT00960219
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1# BID, oral, for 6 weeks
Study: NCT03160885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Study: NCT02928978
Drug: Placebo (for Ruxolitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet (taken by mouth)
Study: NCT03656081
Drug: inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled isotonic saline
Study: NCT01347255
Drug: Daivobet® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 4 weeks
Study: NCT04552873
Drug: Urea
Normalized name: Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered.
Study: NCT00570440
Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 visits - screening/enrollment, 6-months and 12 months
Study: NCT03319940
Drug: CRS Mitigation Strategies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with one of the CRS mitigation strategies.
Study: NCT04191096
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Study: NCT04041050
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT03663933
Drug: Immunosuppression Only Conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
Study: NCT03324425
Drug: Simvastatin 80mg
Normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive simvastatin 80 mg by mouth daily at bedtime
Study: NCT04161755
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
Study: NCT04104139
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03654716
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
Study: NCT04483115
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets; Oral; Single dose
Study: NCT04483115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets; Oral; Single dose
Study: NCT02180867
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02180867
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04002661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT00775853
Drug: 6-[18F]Fluorodopamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04705415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Study: NCT03804372
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
Study: NCT02754583
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/kg
Study: NCT02754583
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
Study: NCT00870974
Drug: [18F]FPEB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
Study: NCT00961792
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
Study: NCT00961792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 0.0 g/kg alcohol to act as placebo
Study: NCT00961792
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
Study: NCT03036462
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v. iron administration
Study: NCT03504241
Drug: mycophenolate acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Study: NCT03662659
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin + capecitabine
Study: NCT00740324
Drug: NPO-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPO-11 after administration of NPO-11
Study: NCT00740324
Drug: NPO-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagons after administration of NPO-11
Study: NCT04152551
Drug: Risedronate Oral Tablet
Normalized name: risedronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonate
Study: NCT01958021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
Study: NCT04576689
Drug: IBE-814 70ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.
Study: NCT04576689
Drug: IBE-814 140ug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.
Study: NCT02798471
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
Study: NCT01742078
Drug: LY2541546 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01742078
Drug: LY2541546 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01742078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC
Study: NCT00630487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
Study: NCT00224432
Drug: probiotics: Lactobacillus GG, lactobacillus Rhamnosus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02422615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
Study: NCT00990808
Drug: Comparator: placebo to MK0859
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK0859 once daily for 4 weeks.
Study: NCT02034292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01739244
Drug: SYL040012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical administration of SYL040012 for 14 consecutive days
Study: NCT01739244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular topical administration of placebo for 14 consecutive days
Study: NCT04029909
Drug: 0.8mg/m2/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study: NCT04029909
Drug: 0.4mg/m2/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study: NCT04657172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ophthalmic solution administered with the Optejet microdose dispenser
Study: NCT00739908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six capsules administered three times a day for six weeks.
Study: NCT00003867
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01440933
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
Study: NCT02972788
Drug: Enamel Matrix Proteins Derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
Study: NCT02020694
Drug: Placebo (for vitamin D)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c.
Study: NCT02576275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
Study: NCT01231438
Drug: Etalpha
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25ug o.d. for 2 weeks
Study: NCT02095717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00404742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO BID
Study: NCT00979121
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
Study: NCT00979121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
Study: NCT01009177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00872729
Drug: Cystagon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H.
Study: NCT00872729
Drug: RP103
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
Study: NCT03649724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
Study: NCT03649724
Drug: Eligard 22.5Mg Suspension for Injection
Normalized name: Eligard 22.5mg Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
Study: NCT02843191
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
Study: NCT02211768
Drug: [18F]-FLT-PET/CT scans
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
Study: NCT03598309
Drug: Lovaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
Study: NCT03610971
Drug: BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
Study: NCT03817398
Drug: Tyrosine Kinase Inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-start TKI medication
Study: NCT04499859
Drug: Ezetimibe 10mg + Rosuvastatin 5mg
Normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin
Study: NCT04499859
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg of Rosuvastatin as a standard treatment for AMI patients
Study: NCT00840047
Drug: Methionine
Normalized name: Methionine
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT00604890
Drug: API 31510 3% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment 3% active cream applied to the lesion
Study: NCT00604890
Drug: API 31510 1.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment 1.5% active cream applied to the lesion
Study: NCT02446964
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV